Meta-analysis on the efficacy and safety of moxifloxacin and levofloxacin in the treatment of urinary tract infections
Abstract
Objective: To evaluate the efficacy and safety of moxifloxacin as well as levofloxacin in the treatment of urinary tract infections,and provide evidence for clinical therapy in China.Methods: We searched the data base in China to collect all the original studies with the key words as moxifloxacin,levofloxacin,urinary tract infection.Data were analyzed by Rev Man 5.1 software.Results: A total of 12 randomized controlled trials involving 1110 patients were included.The values of combined OR for efficacy,clinical cure rate,incidence of adverse reaction and bacterial eradication rate were 1.81(P = 0.01),1.67(P = 0.002),0.75(P = 0.21),1.70(P = 0.10) respectively.Meta-analysis showed that moxifloxacin was more effective than levofloxacin in the treatment of urinary tract infections.However,there was no statistical difference in incidence of adverse reaction and bacterial eradication rate.Subgroup analysis of oral and intravenous administration indicated that oral moxifloxacin was better than levofloxacin in efficacy and clinical cure rate in the treatment of urinary tract infections,while intravenous moxifloxacin showed no statistical difference compared with levofloxacin.Conclusion: Moxifloxacin was an effective and safe antibacterial agent in the treatment of urinary tract infections,and the result should be authenticated in the future with many samples,high quality study,detail method description,etc.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,110 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.